On October 31, 2016 Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, reported two poster presentations at the 16th Biennial Meeting of the International Gynecologic Cancer Society, held October 29-31 in Lisbon, Portugal (Press release, Mateon Therapeutics, OCT 31, 2016, View Source [SID1234516126]). The poster presentations highlighted previously presented data demonstrating results from the treatment of recurrent ovarian cancer with CA4P, and also provided an overview of Mateon’s Phase 2/3 FOCUS Study evaluating the addition of CA4P to current standard of care in patients with platinum-resistant ovarian cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentations
Improved Progression-Free Survival among Women with Measurable Recurrent Ovarian Carcinoma Treated with CA4P Plus Bevacizumab: A Post-Hoc Analysis of GOG-0186I
FOCUS Study: Physician’s Choice Chemotherapy (PCC) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo in Platinum-Resistant Ovarian Cancer (prOC)
The first poster presentation highlighted data from post-hoc analyses from the GOG-0186I Study in patients with measurable disease. Study GOG-0186I evaluated the addition of CA4P to treatment with bevacizumab in patients with recurrent ovarian cancer. In the intent-to-treat population, as well as in a subgroup of patients with measurable disease, the addition of CA4P improved progression-free survival (PFS), including improvements in PFS of 6.2 months for patients with larger tumors. The second poster described the design of the company’s on-going FOCUS Study.
"We believe these highly positive data generated for CA4P in combination with anti-angiogenic agents demonstrate the potential for CA4P to alter the treatment landscape for ovarian cancer, and they provide us with confidence as we move our program forward," stated William D. Schwieterman, M.D., President and Chief Executive Officer of Mateon. "Our clinical investigators are excited to participate in the FOCUS Study, a phase 2/3 trial we initiated in June 2016, and we share their excitement as we look forward to the availability of key data from this study in the second half of 2017."